ICLRNasdaqServices-Commercial Physical & Biological Research
ICON PLC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on May 27, 2026
$168.14−2.04 (-1.20%)
Close on Oct 19, 2026
- Market cap
- $13.01B
- P/E (TTM)
- 300.2
- Dividend yield
- –
ICON PLC revenue by segment
By business segment
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ireland | $3.19B | $3.21B | $3.18B | $3.28B | $3.11B | $2.83B | $2.70B | $2.51B | $2.47B | $2.42B | $2.32B | $2.25B | 38.4% | +2.6% |
| United States | $2.47B | $2.50B | $2.52B | $2.52B | $2.63B | $2.85B | $2.98B | $3.11B | $3.19B | $3.24B | $3.28B | $3.33B | 29.8% | -6.1% |
| Rest of Europe | $1.63B | $1.61B | $1.59B | $1.50B | $1.52B | $1.55B | $1.56B | $1.59B | $1.56B | $1.55B | $1.57B | $1.51B | 19.7% | +7.1% |
| Rest of World | $1.01B | $958.40M | $951.90M | $896.41M | $900.21M | $937.33M | $942.64M | $946.20M | $950.08M | $914.38M | $884.50M | – | 12.2% | +12.0% |
From the segment and revenue-disaggregation notes of ICON's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.